Oz scientist’s breakthrough test may help reduce chemotherapy traumaNovember 14th, 2007 - 1:48 am ICT by admin
He says he has developed a family of molecules that attach themselves to dying or dead cancer cells, which enables doctors to determine whether a particular course of treatment is working within 24 hours of the first dose.
Currently, patients receiving chemotherapy or radiotherapy have to undergo a full cycle of treatment, which can take up to six months, before it can determined whether the tumour has been reduced or has grown.
Professor Hogg says the dye may prevent patients from the side effects in case their combination of cytotoxic drugs proves ineffective. He also says that new test can enable doctors to personalise treatment.
“Chemotherapy has three outcomes - the tumour is reduced, stays the same, or it grows and spreads - but we have no way of knowing which way things are going until the end of a cycle of treatment, or several cycles,” the Sydney Morning Herald quoted him as saying.
“If, at the end of a cycle, we find out the tumour has not been reduced, the oncologist must prescribe a new combination of drugs, or a different treatment, and the patient starts again. This means patients go through a lot of trauma and many don’t have the time to waste on ineffective therapies,” he added.
According to Professor Hogg, patients would be injected with the dye within 24 to 48 hours after the first dose of chemotherapy or radiotherapy, after which a CT scan would be used to see dead or dying cancer cells.
He says that an oncologist can immediately change the treatment in case none of the cancer cells dies.
“This discovery stems from more than 10 years of research focused on the design of molecular probes to study cellular processes,” he said.
“We were working on another project when we found that these molecules attached to dead, cultured cells, so we decided to follow our noses and see where it took us. It is very exciting to be able to tailor treatment and to prevent people from the trauma of going through a chemotherapy cycle for months only to find out it didn’t work,” he added.
He said that the dye was expected to work on the cancers of lung, breast, colon and prostate. However, it would not be suitable for leukaemia.
The US pharmaceutical giant Covidien has bought the development rights in an undisclosed worldwide deal worth tens of millions of dollars in royalties to the university.
The firm hopes to have the dye on the market within five years. Clinical trials with it will begin within two years. (ANI)
- Magnets help fight prostate cancer - Nov 09, 2011
- Scientists develop novel tumour busting technique - Dec 07, 2011
- 'Satnav' device 'could find cancer tumours in body in just one session' - Feb 07, 2011
- Oz scientists' defective gene discovery solves colorectal cancer mystery - Jan 17, 2011
- Herpes virus can treat head and neck cancer - Aug 02, 2010
- New drugs to kill cancers minus side-effects - May 21, 2012
- Radiotherapy the unsung hero of cancer care, say experts - Apr 20, 2010
- Vitamin C hastens brain tumour's death - Feb 20, 2012
- New technique offers fresh hope to lung cancer sufferers - Mar 22, 2011
- Mistletoe helps kiss cancer side-effects goodbye - Dec 19, 2010
- How ovarian cancer resists chemotherapy - Mar 03, 2011
- 'Wonderdrug' keeps breast cancer away - Feb 25, 2011
- Cure cancer in just two hours - Jan 06, 2012
- Herpes virus helps treat cancer patients - Aug 03, 2010
- Golden bullet to kill stubborn cancer cells - Oct 28, 2010